Munksjö: Proposals of the Shareholders' Nomination Board

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 26, 2016 at 2:30 AM

Munksjö: Proposals of the Shareholders' Nomination Board to the Annual General Meeting 2016

Helsinki, Finland, 2016-01-26 08:15 CET (GLOBE NEWSWIRE) -- MUNKSJÖ OYJ, STOCK EXCHANGE RELEASE 26 January 2016 at 8.15 a.m. CET Munksjö: Proposals of the Shareholders' Nomination Board to the Annual General Meeting 2016 The Nomination Board comprises representatives of the three largest shareholders of the company and, in addition, of the Chairman of the Board of Directors and a person nominated by the company's Board of Directors, as expert members. According to its charter, the Nomination Board shall submit its proposals to the Board of Directors at the latest on 31 January preceding the next Annual General Meeting. The Annual General Meeting of Munksjö Oyj will be held on Wednesday, 6 April 2016 at the Finlandia Hall in Helsinki. The notice to convene the Annual General Meeting will be given later on by the Board of Directors. On 16 June 2015, Thomas Ahlström (Ahlström Capital Oy and others), Alexander Ehrnrooth (Viknum AB) and Mikko Mursula (Ilmarinen Mutual Pension Insurance Company) were appointed to the Nomination Board. The Chairman of the Board of Directors Peter Seligson acts as an expert member of the Nomination Board in addition to which the Board of Directors elected Fredrik Cappelen as the second expert member. Among its members, the Nomination Board elected Thomas Ahlström as Chairman. The Nomination Board has at its meeting today submitted the following proposals to the Annual General Meeting 2016; Proposal on the composition of the Board of Directors The number of Board members shall increase by one and shall be confirmed at seven (7). Current members of the Board of Directors; Peter Seligson (born 1964), Sebastian Bondestam (born 1962), Elisabet Salander Björklund (born 1958), Hannele Jakosuo-Jansson (born 1966) and Alexander Ehrnrooth (1974) shall be re-elected. Anna Ohlsson-Leijon and Mats Lindstrand shall be elected as new members of the Board of Directors. Fredrik Cappelen, current member of the Board, has informed the Nomination Board that he is not available for re-election. The proposed members of the Board of Directors have indicated that they, if elected, will elect Peter Seligson as the Chairman of the Board and Elisabet Salander Björklund as the Deputy Chairman of the Board. Ms. Anna Ohlsson-Leijon (born 1968), Swedish citizen, B.Sc. (Bus. Adm.) joined Electrolux AB in 2001 and is currently CFO in the Business Area Major Appliances, EMEA. Her previous positions within the company include SVP, Head of Corporate Control & Services and SVP, Group Treasurer. Ms. Ohlsson-Leijon has held and currently holds positions of trust. She is Deputy Chairman of the Board of Directors of SEB Investment Management AB. Ms. Ohlsson-Leijon is independent of the company and its significant shareholders. Mr. Mats Lindstrand (born 1959), Swedish citizen, M.Sc. (Civil Engineering) and MBA, is currently the Managing Partner at BioMass Capital AB. Mr Lindstrand holds several positions of trust, he is the Chairman of the Board in both Sensec AB and FRISQ AB, a member of the Board of Directors at Papyrus AB, Sirva Inc. and Erik Andersson AB. He is also senior advisor at McKinsey&Company and Triton Advisers Ltd. Mr. Lindstrand is independent of the company and its significant shareholders. The CV's of the current members of the Board of Directors are available at www.munksjo.com. Proposal to amend the Charter of the Nomination Board following the new Corporate Governance Code The Nomination Board will also make a proposal to the Annual General Meeting, which will be included in the notice to the Annual General Meeting, regarding some amendments to its Charter mainly resulting from the entry into force of the new Finnish Corporate Governance Code on 1 January 2016. Also some amendments of a mainly technical nature will be proposed. Proposal on the remuneration of the members of the Board of Directors, the Board committees and the Nomination Board The annual remuneration of the Board of Directors shall remain unchanged with the exception of the Deputy Chairman. The Chairman shall receive EUR 80,000 a year, the Deputy Chairman 50,000 EUR and the ordinary members EUR 40,000 each. The annual remuneration of the Board committees shall remain unchanged. The chairman of the Audit Committee shall annually receive EUR 12,000 and the ordinary members EUR 6,000 each. The chairman of the Remuneration Committee shall annually receive EUR 6,000 and the ordinary members EUR 3,000 each. The chairman of the Nomination Board shall annually receive EUR 6,000 and the ordinary members EUR 3,000 each. Travel expenses are proposed to be reimbursed in accordance with the company's travel policy. Munksjö Oyj For more information, please contact: Gustav Adlercreutz, Secretary of the Board of Directors and the Nomination Board, tel. +358 10 234 5001 Munksjö - Intelligent paper technology Munksjö is a world-leading manufacturer of advanced paper products developed with intelligent paper technology. Munksjö offers customer-specific innovative design and functionality in areas ranging from flooring, kitchens andfurnishings to release papers, consumer-friendly packaging and energy transmission. The transition to a sustainable society is a natural driving force for Munksjö's growth as the products can replace non-renewable materials.This is what "Made by Munksjö" stands for. Given Munksjö's global presence and way of integrating with the customers, the company forms a worldwide service organisation with approximately 2,900 employees and 15 facilities located in France, Sweden, Germany, Italy, Spain, Brazil and China. Munksjö's share is listed on Nasdaq in Helsinki and Stockholm. Read more at www.munksjo.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...